10.1038/nrendo.2017.151 Summary Keywords cost-effectiveness, semaglutide, GLP-1 receptor agonists, type 2 diabetes, China Citation Feng Z, Tong WK, Zhang X and Tang Z (2023) Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China
If the phase 2b trial goes well, its possible the company could trial the combination of bimagrumab and tirzepatide or another one of the GLP-1 agonists in its pipeline
Despite reports of positive outcomes from simultaneous agonism of both GLP-1R and Y2-R, this approach alone has not generated the same clinical benefits as obesity surgery 64,65,66
insurance companies do acknowledge semaglutide's importance for weight loss
Hering and Sheng 2001 ;)
For adults, dosages typically range from 500-2000mg per day